Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,863 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Small portion Clear all
Active, not recruiting Phase 1 Interventional

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264
View directory record Official record
Conditions
Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions
BG-68501, Fulvestrant, BGB-43395
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Recruiting Not applicable Interventional

Gamete Treatment to Correct Fertilization Failure

NCT01944332
View directory record Official record
Conditions
Infertility
Interventions
gamete treatment
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 89 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 25, 2026, 2:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Non-invasive Brain Compliance Measurement Device

NCT01753921
View directory record Official record
Conditions
Diabetes, Diabetic Ketoacidosis
Interventions
this is not an intervention study, MRI
Other · Device
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 16 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

NCT02113813
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations
Interventions
naquotinib, midazolam
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

Comprehensive Shoulder System Nano IDE

NCT01936259
View directory record Official record
Conditions
Joint Disease
Interventions
Mini Stem, Nano
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
21 Years to 90 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Scottsdale, Arizona • Fort Lauderdale, Florida • Fort Wayne, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 25, 2026, 2:56 AM EDT
Terminated Phase 1 Interventional

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

NCT04311710
View directory record Official record
Conditions
Tumor
Interventions
ipilimumab, nivolumab, ENHANZE (rHuPH20)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Hartford, Connecticut • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment Phenotypes for Adolescents With Asthma

NCT04228107
View directory record Official record
Conditions
Asthma in Children, Adherence, Treatment
Interventions
Medication monitoring
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Not applicable Interventional

A Wheelchair Propulsion Training Program

NCT04009187
View directory record Official record
Conditions
Spinal Cord Injuries, Multiple Sclerosis, Amputation, Spina Bifida
Interventions
In-person wheelchair propulsion training program, 30-minute education session
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Not applicable Interventional

Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy

NCT03290677
View directory record Official record
Conditions
Lung Cancer
Interventions
Cryoablation, Biopsy
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer

NCT00171834
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
4
States / cities
Louisville, Kentucky • Columbia, Missouri • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Oct 25, 2026, 2:56 AM EDT
Withdrawn Phase 4 Interventional

Sucrosomial Vs Intravenous Iron for Preoperative Anemia

NCT07287371
View directory record Official record
Conditions
Anemia, Iron Deficiency Anemia
Interventions
Treatment with oral sucrosomial iron, Treatment with intravenous iron
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Active, not recruiting Phase 3 Interventional

Relaxation for Women With Breast Cancer Undergoing Radiotherapy

NCT01202851
View directory record Official record
Conditions
Breast Cancer
Interventions
Relaxation Program, Questionnaires, Saliva Testing
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Withdrawn No phase listed Observational

Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy

NCT01212237
View directory record Official record
Conditions
Brain Tumors
Interventions
fMRI Evaluation
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

NCT04374877
View directory record Official record
Conditions
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Interventions
CHS-388, Pembrolizumab, Toripalimab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Promoting Physical Activity and Fitness Among Underserved Latino Families Living in U.S.-Mexico Border Regions

NCT06596902
View directory record Official record
Conditions
Obesity Prevention, Heart Disease
Interventions
Physical Activity
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
6 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT03098030
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Dinutuximab, Irinotecan, Topotecan
Biological · Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
40
States / cities
Anchorage, Alaska • Goodyear, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

Teaching Parents Reiki for Their Adolescents Receiving Palliative Care

NCT03896165
View directory record Official record
Conditions
Palliative Care, Chronic Disease
Interventions
Reiki
Other
Lead sponsor
Ohio State University
Other
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Akron, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 25, 2026, 2:56 AM EDT
Terminated Not applicable Interventional Results available

Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris

NCT02431494
View directory record Official record
Conditions
Acne Vulgaris, Acne
Interventions
Blue light phototherapy, Microcurrent therapy, Combination of BLP and Microcurrent
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

NCT02840994
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
CV301, Pembrolizumab, Nivolumab
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Tampa, Florida • Indianapolis, Indiana • Metairie, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Satisfaction During Outpatient Versus Inpatient Foley Catheter Induction of Labor

NCT02975167
View directory record Official record
Conditions
Induction of Labor Affected Fetus / Newborn, Cervical Ripening, Patient Satisfaction
Interventions
Outpatient Cervical Ripening, Inpatient Cervical Ripening, Foley catheter placement, Pre-Foley Questionnaire, Post-Foley Questionnaire, Fetal Non-Stress Test
Other · Procedure · Behavioral
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

NCT00246012
View directory record Official record
Conditions
Melanoma
Interventions
Intetumumab, Dacarbazine, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 25, 2026, 2:56 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

NCT02100007
View directory record Official record
Conditions
Solid Tumors
Interventions
ME-344, Topotecan
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 25, 2026, 2:56 AM EDT
Completed No phase listed Observational

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

NCT06587828
View directory record Official record
Conditions
Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis
Interventions
Companion blood samples with procedure
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 2:56 AM EDT